Redeye comments briefly on Sleep Cycle's decision to CE mark its sleep apnea risk detection solution as a Class I medical device in Europe, enabling an earlier EU/UK launch, while deferring further investment in the US FDA pathway until commercial evidence from Europe is in hand.
LÄS MER
